EFPIA Urges Japan To Consider New Funding Models
Executive Summary
Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.
You may also be interested in...
Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies
EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.
Drug Industry Urges Caution Over Japan HTA Plans
Japan's Ministry of Health, Labour and Welfare has decided on a pilot health technology assessment (HTA) program to be initiated in 2016, which will be applied initially only to a limited number of existing approved drugs.